--- title: 'Senior Medical Science Liaison, Central (Multiple Territories) at Praxis Precision Medicines, Inc.' canonical: 'https://feeny.ai/job/senior-medical-science-liaison-central-multiple-territories-praxis-precision-619235mdawnh' type: 'job' last_seen: '2026-11-01' --- # Senior Medical Science Liaison, Central (Multiple Territories) at Praxis Precision Medicines, Inc. - **Company:** Praxis Precision Medicines, Inc. - **Location:** United States - **Compensation:** $190k–$220k - **Work type:** remote - **Posted:** 2026-10-22 - **Last confirmed live:** 2026-11-01 - **Apply:** https://job-boards.greenhouse.io/praxisprecisionmedicines/jobs/5459918008 ## Job description Location: This position may be performed remotely with the required ability to travel up to 60–80%, as needed. - Omaha, NE - Ann Arbor, MI - Grand Rapids, MI - Columbus, OH - Chicago, IL - Indianapolis IN Position Summary: Praxis is seeking a field-based Senior Medical Science Liaisons (MSL) to support prelaunch and launch activities. This role will focus on building trusted relationships with investigators and key stakeholders, delivering high-quality scientific exchange, and ensuring clinical and account readiness in advance of and following potential approval. You will play a critical role in translating clinical data into meaningful insights for the field, educating healthcare professionals on disease state and emerging data, and identifying opportunities and barriers that may impact adoption. Working cross-functionally with Medical, Clinical Development, and Commercial teams, you will help shape and execute field strategy in a dynamic, fast-moving launch environment. This is not a passive, reactive role – you are expected to operate with a high degree of ownership, proactively generate insights, and influence the field through credible, science-driven engagement. We are open to hiring across levels and seek individuals who can operate independently in the field – whether developing into the role or already leading at a high level. Leveling will reflect experience, judgment, and the ability to drive impact in a prelaunch/launch setting. Success in this role requires strong clinical credibility, excellent communication skills, strategic thinking, and comfort operating autonomously in a fast-paced environment. Primary Responsibilities: - Serve as the primary field-based scientific partner to investigators and key stakeholders, building trusted relationships to support prelaunch readiness and successful product adoption. - Deliver high-quality scientific exchange on disease state, clinical data, and the ulixacaltimide profile, ensuring clear understanding of its potential role in treatment. - Educate and prepare clinical sites and healthcare providers for launch, including patient identification, treatment considerations, and integration into clinical practice. - Proactively gather, synthesize, and communicate field insights (e.g., treatment paradigms, barriers to adoption, unmet needs) to inform medical and cross-functional strategy. - Identify and engage key opinion leaders (KOLs) and emerging influencers, supporting the development of advocacy and scientific engagement strategies. - Partner cross-functionally with Medical, Clinical Development, Market Access, and Commercial teams to align on and execute field strategy. - Represent Praxis at scientific congresses and advisory engagements, translating external insights into actionable recommendations. - Maintain deep expertise in CNS/neurology, including evolving treatment landscapes and competitive developments, and apply insights to field strategy. - Ensure all field activities are conducted in compliance with regulatory requirements, GCP standards (as applicable), and Praxis policies and SOPs. Qualifications and Key Success Factors: - Advanced clinical or scientific degree (PharmD, PhD, MD, NP, PA, or RN) - Experience in medical affairs, clinical research, clinical care, or field-based roles within biotech/pharma - Demonstrated ability to interpret and communicate complex scientific and clinical data with clarity and credibility to diverse stakeholders - Strong ownership mindset with the ability to operate independently, navigate ambiguity, and drive impact in a dynamic, prelaunch/launch environment - Proven ability to build and maintain trusted relationships with healthcare professionals, including investigators and key opinion leaders - Experience gathering and translating field insights into actionable recommendations for cross-functional teams - Ability to manage multiple priorities with strong organizational skills, attention to detail, and consistent follow-through - Willingness and ability to travel extensively (~60–80%) in a field-based role - Experience in neurology or CNS disorders preferred - Experience within market access/payor landscape is preferred - Candidates with prior field-based experience and a demonstrated track record of independently driving scientific engagement, shaping clinical perspectives, and contributing to successful pre-launch and launch activities will be considered at a higher level. Annualized Base Salary $190,000—$220,000 USD ## Compensation & Benefits At Praxis, we believe that taking care of our people (and their people) is important, so we provide a world class benefits package to help you thrive.  This includes 99% of the premium paid for medical, dental and vision plans.  We also provide company-paid life insurance, AD&D, disability benefits, and voluntary plans to personalize your coverage. Thinking about the future?  We match dollar-for-dollar up to 6% on eligible 401(k) contributions and sweeten the deal with long-term stock incentives and ESPP.  We provide a discretionary quarterly bonus, an extremely flexible wellness benefit, generous PTO, paid holidays and company-wide shutdowns.  Not to mention, you'll also be joining a phenomenal crew of colleagues who are smart, engaged and inspiring.  We aim high, collaborate hard, and produce results.  Let’s achieve the impossible together! Company Overview Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.  At Praxis we share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders.  Our core Values of Trust, Ownership, Curiosity and Results are foundational to every aspect of our business and are exemplified by each and every one of our team members. Diversity, Equity & Inclusion Guided by our core values, at Praxis Precision Medicines, Inc. we continue to DARE FOR MORE® to advance, promote, and champion diversity, equity, and inclusion by encouraging individuals to bring their authentic selves and perspectives to work each day. We are an equal opportunity employer and committed to providing opportunities to all qualified applicants without regard to race, religious creed, color, gender identity or expression, age, national origin, sexual orientation, disability, genetics, military service and veteran status, or any other characteristic protected by federal, state, or local laws. Attention: Job Scam Alert Praxis has recently become aware of fraudulent job recruitment postings from individuals claiming to represent Praxis. These postings seek financial information in connection with fraudulent opportunities for employment. If you suspect any fraudulent activity or misrepresentation in connection with a Praxis job opportunity, please report it to careers@praxismedicines.com. Praxis does not accept unsolicited submissions from recruitment agencies for open positions. We ask all recruitment agencies to refrain from contacting any Praxis employee regarding any position. All unsolicited resumes submitted by recruitment agencies to any Praxis employee in any form or method will be deemed to be the property of Praxis, and Praxis explicitly reserves the right to hire those candidate(s) without any financial obligation to the recruitment agency. ## About Praxis Precision Medicines, Inc. ## Company Overview - **One-liner**: Praxis Precision Medicines is a fully integrated, clinical-stage biopharmaceutical company developing precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. - **Entity Type**: Public (NASDAQ: PRAX) - **Headquarters**: Boston, Massachusetts, United States - **Founded**: 2015 - **Founders**: Dr. Steven Petrou (Co-Founder and President of R&D) ## Core Business - **Primary Industry**: Biotechnology (CNS / Neuroscience) - **Target Customers**: Patients with rare and prevalent neurological disorders (e.g., essential tremor, developmental and epileptic encephalopathies, focal epilepsy); healthcare providers; payers. - **Mission / Purpose**: To translate genetic insights into the development of life-altering therapies for CNS disorders more effectively and efficiently. ## Products & Services Praxis operates two proprietary platforms and a pipeline of late-stage and early-stage programs: - **Cerebrum™ (Small Molecule Platform)**: Orally available precision therapies targeting ion channels and neuronal circuits. Key assets include: - **Ulixacaltamide**: A T-type calcium channel inhibitor for essential tremor (ET). NDA submission to the FDA expected by mid-February 2026. Breakthrough Therapy Designation. - **Relutrigine**: For SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEEs). NDA submission expected by mid-February 2026. Breakthrough Therapy Designation. Also in Phase 3 for broad DEEs. - **Vormatrigine**: A sodium-channel modulator for focal onset seizures (FOS). In Phase 3 trials (POWER1, POWER2). - **Solidus™ (Antisense Oligonucleotide Platform)**: For genetically defined CNS disorders. Key asset: - **Elsunersen**: An ASO designed to reduce SCN2A gene expression for early-seizure-onset SCN2A-DEE. In Phase 3 (EMBRAVE3). Orphan Drug Designation. - **Early-Stage Pipeline**: Preclinical candidates (PRAX-020, PRAX-080, PRAX-090, PRAX-100) targeting other genetic epilepsies and neurodevelopmental disorders. ## Market Standing - **Market Cap**: ~$156.0 million (as of mid-2026 data) [linkedin.com] - **Key Metric (Revenue/Funding)**: Annual revenue reported at ~$8.6M (pre-commercial stage). Pro forma cash, cash equivalents, and marketable securities stand at **$1.5 billion** following a public offering in January 2026 that raised ~$621 million [ir.praxismedicines.com]. - **Notable Investors/Partners**: Ionis Pharmaceuticals, Inc. (collaboration on elsunersen); RogCon, Inc. (license agreement). - **Growth Signals**: - Rapidly scaling headcount: 166 employees (+49.7% year-over-year) [linkedin.com]. - Transformation to a commercial-stage company: Preparing for two NDA submissions by mid-February 2026. - Combined peak revenue estimates for its four late-stage assets expected to exceed **$20 billion** [ir.praxismedicines.com]. - Active hiring: 31 open positions in mid-2026 (up 933% year-over-year) [linkedin.com]. ## Competitive Advantages - **Precision Neuroscience Moat**: Deep understanding of shared biological targets and circuits in the brain derived from genetic epilepsies. - **Proprietary Dual Platforms**: Leveraging both small molecule (Cerebrum) and ASO (Solidus) modalities to address a wide range of CNS disorders. - **Breakthrough Therapy Designations**: Both lead assets (ulixacaltamide, relutrigine) have FDA Breakthrough Therapy Designation, accelerating development and review. - **Strong Cash Position**: $1.5 billion pro forma cash provides a long runway through multiple potential product launches and pipeline expansion. - **Late-Stage Pipeline**: Four late-stage product candidates approaching potential commercial launch, de-risking the company substantially. ## Strategic Focus - **Commercial Launch Readiness**: Building out commercial infrastructure, sales force, and patient support programs in parallel with regulatory submissions. - **Pipeline Expansion**: Declaring multiple new drug candidates from both Cerebrum and Solidus platforms in 2026. - **Lifecycle Management**: Exploring indication expansion for existing assets (e.g., relutrigine in broad DEEs via the EMERALD study; vormatrigine for monotherapy FOS). - **Global Reach**: Operating in 5 countries (US, Australia, India, Colombia, Brazil) with a growing workforce. ## Why Work Here - **Mission-Driven Work**: Opportunity to deliver transformative therapies to patients with severe, underserved CNS disorders. - **Growth Trajectory**: The company is at a pivotal inflection point, transitioning from a clinical-stage to a commercial-stage organization — offering dynamic career growth. - **Remote-First Culture**: The vast majority of open positions across all departments (Clinical, Medical, Commercial, Finance, Legal, etc.) are listed as **"United States - Remote"** [greenhouse.io]. This includes roles like Director, Commercial Compliance; Senior Clinical Trial Manager; and Director, Field Reimbursement. - **Global Talent**: Engineering and technical roles are open internationally (e.g., Software Engineer in Brazil) [greenhouse.io]. - **Strong Leadership**: Recent appointments of experienced pharmaceutical executives (Jeffrey B. Kinder, Stuart Arbuckle) and internal promotions (Megan Sniecinski to COO). - **Compensation**: Employee reviews indicate a strong **Compensation rating of 4.0/5.0**, though overall culture and career ratings are lower (2.8 and 2.7 respectively on LinkedIn) [linkedin.com]. - **Workforce Demographics**: A high proportion of Director-level roles are open (20% of workforce), alongside specialists and senior IC roles, suggesting significant opportunities for leadership-level hires. ## Sources 1. [greenhouse.io](http://job-boards.greenhouse.io/praxisprecisionmedicines) - Jobs at Praxis Precision Medicines, Inc. 2. [ir.praxismedicines.com](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-enters-its-next-chapter-following) - Press Release: Business Outlook and Priorities for 2026 3. [linkedin.com](https://www.linkedin.com/company/praxis-precision-medicines-inc) - LinkedIn Company Profile 4. [stockanalysis.com](https://stockanalysis.com/stocks/prax/company/) - Company Profile & Key Executives ## Other roles at Praxis Precision Medicines, Inc. - [HCP Personal Marketing Lead - Epilepsy](https://feeny.ai/job/hcp-personal-marketing-lead-epilepsy-praxis-precision-medicines-inc-united-nb0v6h4gcefv) — United States - [Account Specialist (Athens, GA)](https://feeny.ai/job/account-specialist-athens-ga-praxis-precision-medicines-inc-united-states-sqgrwcdhqgef) — United States - [Account Specialist (Macon, GA)](https://feeny.ai/job/account-specialist-macon-ga-praxis-precision-medicines-inc-united-states-02ed9b2mpacq) — United States - [Account Specialist (Peachtree City, GA)](https://feeny.ai/job/account-specialist-peachtree-city-ga-praxis-precision-medicines-inc-united-a41te9f4fvga) — United States - [Account Specialist (Dayton, OH)](https://feeny.ai/job/account-specialist-dayton-oh-praxis-precision-medicines-inc-united-states-rsghyfn9t17h) — United States - [Account Specialist (Toledo, OH)](https://feeny.ai/job/account-specialist-toledo-oh-praxis-precision-medicines-inc-united-states-2sbnnhgw45fz) — United States - [Account Specialist (Cleveland, OH)](https://feeny.ai/job/account-specialist-cleveland-oh-praxis-precision-medicines-inc-united-states-81bfs3jf9cea) — United States - [Senior Medical Science Liaison, West (Multiple Territories)](https://feeny.ai/job/senior-medical-science-liaison-west-multiple-territories-praxis-precision-5zgyxw9b700m) — United States - [Senior Medical Science Liaison, Southeast (Multiple Territories)](https://feeny.ai/job/senior-medical-science-liaison-southeast-multiple-territories-praxis-precision-zbz84w4ah0qt) — United States - [Senior Medical Science Liaison, South (Multiple Territories)](https://feeny.ai/job/senior-medical-science-liaison-south-multiple-territories-praxis-precision-g4ek6hdaj0vy) — United States